Literature DB >> 12707486

Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia?

Medaim Yanik1, Huseyin Vural, Abdurrahim Kocyigit, Hamdi Tutkun, Süleyman Salih Zoroglu, Hasan Herken, Haluk Asuman Savaş, Alpay Köylü, Omer Akyol.   

Abstract

The reciprocal regulation of arginase and nitric oxide synthase (NOS) in L-arginine-metabolizing pathways has been demonstrated. There are various evidences of the role of the nitric oxide (NO) in several neuropsychiatric disorders including schizophrenia. However, there is no study which has investigated the role of arginase as an important part of the arginine regulatory system affecting NOS activity in schizophrenia. This study aims to investigate arginase, manganese (Mn) and total nitrite levels (a metabolite of NO) and their relationship to the arginine-NO pathway in patients with schizophrenia. Arginase activities, Mn and total nitrite levels were measured in plasma from 46 patients with schizophrenia and 32 healthy control subjects. Plasma arginase activities and Mn were found to be significantly lower and total nitrite level higher in patients with schizophrenia compared with controls. Our results suggest that the arginine-NO pathway is involved in the pathogenesis of schizophrenia. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707486     DOI: 10.1159/000070010

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  19 in total

Review 1.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

2.  Role of oxidative stress in the pathophysiology of Toxoplasma gondii infection.

Authors:  Gungor Cagdas Dincel; Hasan Tarik Atmaca
Journal:  Int J Immunopathol Pharmacol       Date:  2016-03-10       Impact factor: 3.219

Review 3.  Possible mechanisms of neurodegeneration in schizophrenia.

Authors:  Iván Pérez-Neri; Jesús Ramírez-Bermúdez; Sergio Montes; Camilo Ríos
Journal:  Neurochem Res       Date:  2006-09-28       Impact factor: 3.996

4.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

Review 5.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

Review 6.  Manganese-enhanced MRI: an exceptional tool in translational neuroimaging.

Authors:  Afonso C Silva; Nicholas A Bock
Journal:  Schizophr Bull       Date:  2008-06-11       Impact factor: 9.306

7.  Elevated plasma F2-isoprostane levels in schizophrenia.

Authors:  Ellen E Lee; Lisa T Eyler; Owen M Wolkowitz; Averria Sirkin Martin; Chase Reuter; Helena Kraemer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2016-06-16       Impact factor: 4.939

Review 8.  Neurobiology of schizophrenia onset.

Authors:  Tsung-Ung W Woo
Journal:  Curr Top Behav Neurosci       Date:  2014

9.  Endothelial function and lipid profile of individuals with schizophrenia participating in a supported employment program.

Authors:  Jordana Lectzow de-Oliveira; Ivy Reichert da-Silva; Thiago Rozales Ramis; Carmen Vera Ferreira; Sandra Maria Soares; Jerri Luiz Ribeiro; Gilson Pires Dorneles; Luciane Carniel Wagner
Journal:  Rev Bras Med Trab       Date:  2018-06-01

10.  Schizophrenia shows a unique metabolomics signature in plasma.

Authors:  Y He; Z Yu; I Giegling; L Xie; A M Hartmann; C Prehn; J Adamski; R Kahn; Y Li; T Illig; R Wang-Sattler; D Rujescu
Journal:  Transl Psychiatry       Date:  2012-08-14       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.